Fig. 5.

Effect of the general HDAC inhibitor 4-PBA on myotube and myobundle function. A Myotubes were differentiated in a 6-well plate and treated with 5 mM 4-PBA for 18 h immediately prior to 2-DG uptake at the 2 week differentiation time point. N = 3 donors, n = 3 wells per condition per donor. B Myobundles were treated with 5 mM 4-PBA for 18 h immediately prior to 2-DG uptake at the 2 week differentiation time point. N = 3 donors, n = 3−4 myobundles per condition per donor. C–E Myobundles were treated with 5 mM 4-PBA for 18 h immediately prior to measuring twitch and tetanus contractile force, percent fatigue, and twitch kinetics at the 2 week differentiation time point. N = 3 donors, n = 3−4 myobundles per condition per donor. For all panels, N = 3 donors, n = 3 myobundles per condition per donor. *p < 0.05, **p < 0.01, ***p < 0.001 when compared with the same insulin condition or contractile function measurement in the no treatment group.# p < 0.05 when compared with the no insulin condition within the treatment group. Data in all panels presented as mean ± S.E.M